Biotechnology
Thermo Fisher Announces 160 Layoffs in Massachusetts as Part of Viral Vector Overhaul
Thermo Fisher, layoffs, Massachusetts, viral vector, biotechnology, restructuring
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying
Historic Settlement: Lacks Family Reaches Agreement with Thermo Fisher Scientific Over Unjust Enrichment from HeLa Cells
Henrietta Lacks, HeLa cells, Thermo Fisher Scientific, unjust enrichment, racial injustice, medical ethics, consent, biotechnology, settlement.
Jade Biosciences and Aerovate Therapeutics Announce Strategic Merger to Advance Autoimmune Disease Therapies
Reverse merger, Jade Biosciences, Aerovate Therapeutics, Paragon Therapeutics, Autoimmune diseases, JADE-001, IgA nephropathy (IgAN), Biotechnology
Coya Therapeutics Faces Setback as COYA 302 Delivers Mixed Results in Mid-Stage Study for Frontotemporal Dementia
Coya Therapeutics, COYA 302, Frontotemporal Dementia, Alzheimer’s Disease, Neurodegenerative Diseases, Clinical Trials, Biotechnology
Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline
Lyell Immunopharma, ImmPACT Bio, CAR T-cell therapy, pipeline acquisition, biotechnology, cancer treatment, autoimmune diseases
Terray Therapeutics Secures $120M Series B Funding to Advance AI-Driven Small Molecule Drug Development
AI-driven drug discovery, small molecule development, Terray Therapeutics, series B funding, biotechnology, pharmaceutical innovation.
Eli Lilly Expands Global Innovation Reach with New Research Centers in China
Eli Lilly, China, Research Centers, Innovation, Gateway Labs, Biotechnology, Drug Development
Pfizer and Triana Biomedicines Collaborate on Molecular Glue Discovery for Cancer and Other Diseases in $1.5 Billion Deal
Pfizer, Triana Biomedicines, molecular glue, cancer, oncology, drug discovery, biotechnology, pharmaceuticals
Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4
Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases